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Definition and epidemiology 
of lupus nephritis
Systemic lupus erythematosus (SLE) is a chronic 
multi-systemic autoimmune disorder with a pre-
dilection for young females. Kidney disease in SLE 
(also known as lupus nephritis (LN)) is a common manifestation of 
SLE and constitutes an important prognostic factor for such patients. 
Up to 50% of SLE patients have abnormalities of renal function or 
urine (proteinuria, haematuria or cellular casts) early in the course 
of the disease, whereas approximately 80% may later develop overt 
abnormalities of renal function.[1] According to the 2012 Systemic 
Lupus International Collaborating Clinics Classification (SLICC) 
criteria for the diagnosis of SLE, kidney disease is present when a 
patient with SLE presents with persistent proteinuria (>0.5 g/24 h) or 
cellular red cell casts.[2] LN is a major determinant of morbidity and 
mortality in SLE patients. A South African (SA) study has shown that 
over half of 226 SLE patients from a lupus clinic had either died or 
been lost to follow-up at 55 months, and LN was the only significant 
factor associated with mortality on multivariate analysis, with a 
5-year survival rate of 60%.[3]
Classification 
The classification of LN is based on histological features, using the 
International Society of Nephrology (ISN) and Renal Pathology 
Society (RPS) criteria developed in 2003 (Table 1).[4] Although 
the classification is mainly glomerulocentric, it includes features 
of tubulo-interstitial disease, from which features of chronicity 
can be determined. The relationship between the histological 
class of LN and clinical course of the disease is well recognised. 
Patients with class II and class V (pure membranous LN) disease 
usually have a slow decline in renal function over long periods of 
observation. In contrast, patients with class III and class IV (or 
those with mixed class V) disease mostly have a more aggressive 
course of disease. Various studies have shown that the proliferative 
forms of LN (i.e. class III, class IV and mixed class V) occur 
more frequently than the other histological morphologies. In 
Cape Town, of 251 patients with biopsy-proven LN, 63% had 
proliferative LN.[5]
Diagnosis 
One of the major challenges with regard to SLE is its early recognition 
and diagnosis. Many physicians assume that SLE is a rare condition in 
Africa – it is therefore seldom considered as a differential diagnosis, 
except when patients present with classic features, such as malar 
rash and swollen painful joints of the hands and feet. Hence, many 
patients tend to remain ill for prolonged periods before the diagnosis 
is made. In some instances, chronic damage to organs including the 
kidneys would have occurred.
Role of urinalysis and urine microscopy
LN is unlikely to present alone – it often manifests with other extrarenal 
features such as joint pain, malar rash, oral ulcers and photosensitivity. The 
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Table 1. Abbreviated International Society of Nephrology/Renal 
Pathology Society classification of lupus nephritis (2003)[4]
Class I Minimal mesangial lupus nephritis
Class II Mesangial proliferative lupus nephritis
Class III Focal lupus nephritis (<50% involvement)
Class IV
Diffuse segmental or diffuse global lupus nephritis 
(≥50% involvement)
Class V Membranous lupus nephritis*
Class VI Advanced sclerosing lupus nephritis
* Can be pure membranous lupus nephritis or mixed class V if combined with class III or class IV.
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patient with LN is likely to present with neph-
ritic syndrome (oliguria, minimal proteinuria, 
haematuria, hypertension and azotaemia) or with 
features of nephrotic syndrome (anasarca, heavy 
proteinuria and hypoalbuminaemia). Urinalysis 
(dipstick and microscopic examination) presents 
the best opportunity for early identification of LN 
as a dipstick is likely to show the presence of blood 
and protein in the urine and urine microscopy 
enables identification of various urinary casts 
(red cells, granular, hyaline). LN must be strongly 
suspected in any SLE patient with high titres of 
double-stranded DNA (dsDNA) and a positive 
dipstick for blood. Urinalysis features have been 
shown to be correlated with the presence of 
proliferative class LN.[5] Therefore, every SLE 
patient should have a urinalysis performed at 
every clinic visit. 
Role of lupus auto-antibodies 
(antinuclear antibody and dsDNA) 
and complements (C3/C4)
Auto-antibodies in SLE and complements 
(C3/C4) are known to be elevated or lowered, 
respectively, in patients with increased disease 
activity, especially in those with proliferative LN 
(class III, class IV and mixed class V). One 
study found proliferative LN to be significantly 
correlated with haematuria on dipstick 
(p<0.0001), proteinuria on dipstick (p=0.042), 
low complement C3 (p<0.0001), low complement 
C4 (p=0.009) and positive dsDNA (p=0.039).[5] 
Role of renal biopsy
The definitive diagnosis of LN requires a 
kidney biopsy. Renal histology also enables 
classification of LN and assists in the prognosis. 
All guidelines recommend a renal biopsy when 
there is a suspicion of renal involvement, as 
clinical and laboratory parameters, although 
useful, cannot accurately predict the histological 
class. The indication for a renal biopsy in SLE 
patients includes persistent decline in renal 
function, proteinuria (≥1.0 g/24 h) or proteinuria 
(≥0.5 g/24 h) if associated with haematuria 
(5 red blood cells (RBCs)/high-power field) 
and active urinary sediment (granular casts, 
white blood cell (WBC) casts, RBC casts). It 
is recommended that the biopsy be examined 
by light microscopy, immunofluorescence (or 
immunohistochemistry) and where possible 
by electron microscopy.[6] Quantification of 
activity and chronicity indices and description 
of vascular and interstitial lesions are also 
recommended. A repeat renal biopsy is indicated 
if there is evidence of worsening of the disease 
or disease refractory to treatment, evidence of 
relapse (to show transformation or progression 
in histological class or change in activity and 
chronicity cores) and to demonstrate other 
pathologies. Fig. 1 shows the renal histology in a 
patient with class IV LN.
Treatment 
The treatment of LN is dictated by the 
class of the disease and degree of activity 
and chronicity indices. All patients should 
receive adjuvant therapies as indicated 
and if tolerated. There should be a risk-
benefit evaluation when deciding whether 
to use immunosuppression in patients with 
increased chronicity indices (i.e. glomerular 
sclerosis with tubulo-interstitial fibrosis) 
because of the increased risk of side-effects 
of treatment. The approach to treatment 
often involves two phases for patients with 
proliferative LN (class III, class IV and 
mixed class V).
Induction therapy 
Fig. 2 summarises the common approaches 
used for induction for the different classes 
of LN.[7,8] Induction therapy is not used for 
Fig. 1. Renal histology of a patient with class IV lupus nephritis (white arrow shows a glomerulus with 
cellular crescent; black broken arrows show adjacent tubules with red cell casts).
Biopsy-conrmed lupus nephritis











• Blood pressure control
Nephrotic:








Vitamin D and calcium supplements (for bone protection)
Aspirin (for CV protection)





Fig. 2. Treatment approach for patients with lupus nephritis (APLS = antiphospholipid syndrome; 
AZA = azathioprine; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor 
blocker; CNI = calcineurin inhibitor; CS = corticosteroid; CYC = cyclophosphamide; DVT = deep-vein 
thrombosis; MMF = mycophenolate mofetil; CV = cardiovascular).
* Immunosuppression to be dictated by extrarenal manifestations.
† Patients should be prepared for renal replacement therapy (dialysis/ transplantation).
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patients with class I, II, V (pure class V with sub-nephrotic range 
proteinuria) and VI LN. The approach to induction involves the 
use of 3 consecutive pulses of intravenous methylprednisolone 
(500 - 750  mg daily) together with another immunosuppressive: 
cyclophosphamide (CYC) (daily oral or monthly intravenous pulse 
therapy) or mycophenolate mofetil (MMF). The patient should 
continue on oral prednisone (1  mg/kg/day) after completing the 
pulse treatment with methylprednisolone. CYC is often the agent 
of choice for many clinicians owing to easy accessibility and cost; 
however, the use of MMF is increasing. Various studies have assessed 
the efficacy and safety of CYC with MMF or placebo for induction 
therapy in patients with LN (reviewed in depth by Chan[9]). The 
recommended duration of induction therapy is 6 months; during this 
time, the dose of oral corticosteroid should be weaned. 
Maintenance therapy
Treatment administered during the induction phase of therapy 
is de-escalated in the maintenance phase. The goal of the latter 
phase is to maintain the response (remission) gained during the 
induction phase and therefore to retard progression of chronic 
kidney disease. Immunosuppressive agents commonly used include 
MMF, azathioprine (AZA), and corticosteroids. Calcineurin inhi-
bitors may be used in special circumstances, such as in cases 
of intolerance to MMF or AZA or in patients with persistent 
heavy proteinuria (Fig. 2). There is currently no consensus on the 
duration of maintenance therapy. Nonetheless, the decision to 
withdraw maintenance immunosuppression should be guided by 
sustained complete clinical response over a period of at least 2 years. 
Withdrawal should be done gradually, starting with glucocorticoids 
before withdrawing immunosuppressive agents.[8] In debilitating 
or life-threatening complications of immunosuppression, therapy 
should be withdrawn. 
Adjunctive therapies 
Adjunctive therapies are usually started during the induction phase 
of treatment and although some need to be discontinued after 
completing this therapy, others will need to be continued during the 
maintenance phase. Commonly recommended adjunctive therapies 
in LN include:
• Renin angiotensin aldosterone system (RAAS) inhibition for 
proteinuria and blood pressure treatment (target <130/80 mmHg).
• Bone protection with calcium and vitamin D supplements.
• Chloroquine for all patients (unless contraindicated, e.g. visual 
disturbance).
• Treatment of hyperlipidaemia with statins (target low-density 
lipoprotein <2.6 mmol/L).
• Low-dose acetylsalicylic acid in patients with antiphospholipid 
syndrome.
• Anticoagulant to be considered in patients with nephrotic 
syndrome and albumin <20 g/L.
• Avoid vaccination with live or attenuated viruses during immune 
suppression.
• Tuberculosis prophylaxis with isoniazid (for those in highly 
endemic TB regions).
Treatment of refractory LN
Fewer than 50% of patients are able to achieve complete remission 
during the 6 months of induction therapy. It may take up to 2 years to 
reach remission in many patients. Switching to an alternative agent is 
recommended for patients who fail to improve within 3 - 4 months, or do 
not achieve a partial response after 6 - 12 months or a complete response 
after 2 years of treatment. Treatment options include switching from 
MMF to CYC or from CYC to MMF; rituximab may be given as 
add-on treatment or monotherapy. Other options include the use 
of calcineurin inhibitors, intravenous immunoglobulin and plasma 
exchange for patients with rapidly progressive glomerulonephritis.
Treatment of class VI LN
Immunosuppression for class VI patients must be dictated by 
extrarenal manifestations of SLE. These patients should be prepared 
for renal replacement therapy (haemodialysis, peritoneal dialysis or 
transplantation). Treatment and prevention of cardiovascular risk 
factors (e.g. blood pressure control, statins for dyslipidaemia) should 
be continued. 
Monitoring for drug toxicities and disease activity
It is recommended that body weight, blood pressure, serum creatinine, 
urinalysis (for proteinuria and urinary sediment), C3/C4, anti-dsDNA, 
serum albumin and full blood count be performed at each clinic 
visit. Patients with active nephritis should be seen monthly or more 
frequently, while those with no active disease should be seen twice 
yearly or quarterly. This ensures monitoring of disease activity. 
Useful approaches to monitoring for drug toxicities/side-effects are 
summarised in Table 2.
Treatment options for pregnant LN patients
Pregnant LN patients often present a challenge to the clinician, as pregnancy 
can be a trigger for increased disease activity. Some guidelines therefore 
recommend that pregnancy should not be planned until remission has 
been achieved and maintained for at least 6 months.[7,8] Pregnant patients 
with LN have an increased risk of pre-eclampsia, preterm delivery and 
fetal loss. They should therefore be managed by a multidisciplinary team 
Table 2. Adverse effects of drugs and approach to monitoring in patients with lupus nephritis
Medication Adverse effect Monitoring approach
Glucocorticoids Glucose intolerance/diabetes mellitus, osteoporosis, hypertension, 
gastritis, cataracts, avascular necrosis of femur, cushingoid appearance 
Blood glucose measurement, bone mineral density 
assessment, blood pressure monitoring, weight monitoring
Cyclophosphamide Leukopenia, menstrual disorders, gonadal failure, 
haemorrhagic cystitis




Leukopenia, hypercholesterolaemia Full blood count, serum cholesterol, gastrointestinal 
disturbances and neurotoxicity assessment
Azathioprine Leukopenia, hepatotoxicity, pancreatitis Full blood count, liver function tests, dose adjustment 
for concomitant allopurinol use
Chloroquine Retinopathy Annual ophthalmology examination
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of clinicians (obstetricians, rheumatologists and 
nephrologists). Angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, MMF 
and CYC are prohibited during pregnancy 
(Table 3).[10] Prednisone, AZA and calcineurin 
inhibitors may be continued during pregnancy. 
Labetalol, methyldopa and nifedipine may be 
used for control of blood pressure, and low-
dose acetylsalicylic acid should be considered to 
reduce the risk of pre-eclampsia.
Definitions of response to treatment 
and flares in LN
There is consensus for defining a complete 
response as inactive urinary sediment, a 
decrease in proteinuria to ≤0.2 g/day and 
normal or stable renal function (within 
10% of normal glomerular filtration rate 
(GFR) if previously abnormal).[11] Partial 
response is taken as improvement of renal 
function, marked by inactive sediment, 
proteinuria ≤0.5 g/day, with normal GFR 
or stable renal function. A flare is defined 
as an increase in disease activity requiring 
more intensive therapy. It is indicated by an 
increase in proteinuria or serum creatinine, 
abnormal urinary sediment or a reduction 
in creatinine clearance due to active disease. 
There are two main types of flare:
• Nephrotic flare – proteinuria >2 g/day.
• Nephritic flare typified by an increasing 
anti-dsDNA, low C3/C4, active urine 
sediment, and worsening serum creatinine. 
LN flare surveillance during visits includes 
urinanalysis (dipstick and microscopy) for 
proteinuria and cellular casts such as RBC 
casts, WBC casts, and serum creatinine 
determination. Significant proteinuria on 
dipstick analysis should be followed by a 
quantitative protein analysis. 
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Table 3. Use of immunosuppressive and adjunctive agents in pregnancy
Drug
May the drug be 
used in pregnancy? Side-effects
Glucocorticoids Yes High risk of gestational diabetes and 
PROM
Cytotoxic agents
• Cyclophosphamide No Increased fetal loss and abnormalities
• Azathioprine Yes -
• Mycophenolate mofetil No May cause congenital abnormalities
• Chloroquine Yes -
Calcineurin inhibitors
• Cyclosporin Yes Increased risk of obstetric cholestasis
• Tacrolimus Yes Increased risk of gestational diabetes
• Rituximab No Lack of data
RAAS blockade No May cause congenital defects in the renal, 
pulmonary, cardiac, skeletal and 
nervous systems
PROM = premature rupture of membranes; RAAS = renin angiotensin aldosterone system. Adapted from Day CJ, et al.[10] 
